Open AccessHEPATIC DYSFUNCTION FOLLOWING T-CELL-DEPLETED ALLOGENEIC BONE MARROW TRANSPLANTATION
Author(s) -
Robert J. Soiffer,
Keith Dear,
SN Rabinowe,
Kenneth C. Anderson,
Arnold S. Freedman,
Christine Murray,
Nancy J. Tarbell,
Peter Mauch,
Lee M. Nadler,
Jérôme Ritz
Publication year - 1991
Publication title -
transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199112000-00015
Subject(s) - medicine , hepatic veno occlusive disease , cyclophosphamide , bone marrow , gastroenterology , total body irradiation , liver function tests , transplantation , bilirubin , surgery , liver function , complication , incidence (geometry) , chemotherapy , hematopoietic stem cell transplantation , physics , optics
We reviewed the medical records of 97 patients undergoing T cell-depleted allogeneic bone marrow transplantation at our institution from 1984 to 1990 to determine the incidence of hepatic dysfunction, including venoocclusive disease of the liver following BMT. All patients received allogeneic marrow that had been purged with monoclonal antibody to the CD6 surface antigen (T12) and rabbit complement as the sole method of graft-versus-host disease prophylaxis. No additional immunosuppressive agents were routinely administered to these patients. Overall, 55% of patients in our series developed two-fold elevations in serum bilirubin, SGOT, or alkaline phosphatase within the first 30 days following BMT. A five-fold elevation in any liver function test was noted in only 19% of patients. Logistic regression analysis revealed that the presence of GVHD, female sex, and administration of amphotericin B all were independently associated with laboratory evidence of hepatic dysfunction. While LFT abnormalities were common in our series, they were generally mild, and the development of VOD was rare. Only three patients (3.1%) fulfilled clinical criteria sufficient to establish a diagnosis of VOD. Among the 86 patients whose ablative regimen consisted of cyclophosphamide (60 mg/kg x2) and total-body irradiation (1200-1400 cGy in 200 cGy fractions), only 1 patient (1.2%) developed VOD. Our experience suggests that patients undergoing allogeneic BMT are at low risk for VOD and other serious hepatic complications when they receive high-dose cyclophosphamide, fractionated TBI, and T cell-depleted marrow without hepatotoxic medications for GVHD prophylaxis.